Group 1 - Three new SPACs have recently listed on the US stock market, raising a total of $590 million [1] - Buda Juice plans to use the $20 million raised for developing and constructing production facilities, marketing, and working capital [5] - Buda Juice reported revenue of $9.71 million and a net profit of $2.86 million for the nine months ending September 30, 2025 [5] Group 2 - Bleichroeder Acquisition II issued 25 million units at $10 each, raising $250 million, and will list on NASDAQ under the ticker BBCQ [5] - Bleichroeder Acquisition II is a special purpose acquisition company targeting firms in digital infrastructure, AI, digital trust technology, cloud computing, robotics, and software development, focusing on North America and Europe [8]

Core Viewpoint - Buda Juice, a Texas-based company specializing in private label and contract citrus beverages, announced its IPO terms, aiming to raise $22 million by issuing 2.7 million shares priced between $7.50 and $9.00 per share, which would value the company at approximately $99 million at the midpoint of the price range [1] Group 1: Company Overview - Buda Juice is headquartered in Dallas, Texas, and was founded in 2013 [1] - The company reported revenue of $12 million for the 12 months ending June 30, 2025 [1] - Buda Juice plans to list on the New York Stock Exchange under the ticker symbol "BUDA" [1] Group 2: Business Strategy - The company is pioneering the "UltraFresh" juice category through an end-to-end cold chain platform [1] - Buda Juice's product lineup includes fresh-squeezed citrus juices and health drinks for various brand lines and retail clients, showcasing both brand diversification and contract manufacturing capabilities [1] - The company currently operates a production facility in Dallas and plans to establish new facilities in South Carolina by 2026 and in Arizona/Nevada by 2027 [1] Group 3: IPO Details - The IPO will consist of 2.7 million shares, with 25% being secondary shares [1] - The price range for the shares is set between $7.50 and $9.00 [1] - MDB Capital Group is the exclusive underwriter for this offering [1]